Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study

HIV Clinical Trials
Enric PedrolJosé R Blanco Ramos

Abstract

Our aim is to describe the impact of emtricitabine (FTC)/tenofovir (TDF) versus other nucleoside reverse transcriptase inhibitor (NRTIs)-based regimens on renal function of human immunodeficiency virus (HIV) naïve patients >50 years old who started combination antiretroviral therapy (cART). National, retrospective cohort analysis of patients >50 years old when they started cART (January 1, 2006-December 31, 2009). We compared renal safety (changes in estimated glomerular filtration rate [eGFR] during the first year, and time to renal events during 4 years of follow-up) in FTC/TDF versus non-FTC/TDF users. Among FTC/TDF users, we compared protease inhibitors vs non-nucleoside reverse transcriptase inhibitors and Lopinavir/ritonavir vs Efavirenz. We included 103 patients: median age: 54.9 years, 84% males, median CD4 count 247 cells/μl, median viral load 4.7 log; median follow up 18 months (max: 48 months); 73 started with FTC/TDF and 30 with other NRTIs. Change in eGFR was significantly worse for ritonavir-boosted lopinavir (LPV/r) vs efavirenz (EFV) users in the FTC/TDF group (71.2 vs 98.9 ml/min/1.73 m(2) at month 12, P < 0.05). The risk of renal events (progression to an Chronic Kidney Disease Epidemiology Collaboration value...Continue Reading

References

Apr 21, 2004·AIDS·Hassane IzzedineGilbert Deray
Jul 14, 2004·JAMA : the Journal of the American Medical Association·Joel E GallantUNKNOWN 903 Study Group
May 13, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Samir K GuptaLynda A Szczech
Dec 16, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Anthony E ZimmermannGregory Braden
Nov 3, 2006·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Brian P KearneyAndrew K Cheng
May 16, 2007·AIDS·Amanda MocroftJens D Lundgren
Jan 4, 2008·The Journal of Infectious Diseases·Miguel GoicoecheaUNKNOWN California Collaborative Treatment Group 578 Team
Oct 25, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jonathan WinstonBenjamin Young
Feb 20, 2009·HIV Medicine·L J CampbellF A Post
Apr 14, 2009·AIDS Research and Human Retroviruses·Ei Kinai, Hideji Hanabusa
May 6, 2009·Annals of Internal Medicine·Andrew S LeveyUNKNOWN CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
Jul 14, 2009·AIDS Patient Care and STDs·Benjamin YoungUNKNOWN HIV Outpatient Study (HOPS) Investigators
Dec 17, 2009·HIV Medicine·E K DétiUNKNOWN Groupe d'Epidémiologie Clinique du SIDA en Aquitaine
Jun 3, 2010·AIDS Patient Care and STDs·Nancy Crum-CianfloneStephanie Brodine
Feb 4, 2011·The Journal of Infectious Diseases·Rubin LubomirovUNKNOWN Swiss HIV Cohort Study
Mar 12, 2011·The Journal of Antimicrobial Chemotherapy·E Paul O'DonnellFrank J Palella
Oct 15, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Giovanni GuaraldiFrank Palella
Oct 15, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Barbara HasseUNKNOWN Swiss HIV Cohort Study

❮ Previous
Next ❯

Citations

Oct 9, 2020·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Mariantonietta PisaturoNicola Coppola

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.